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Abstract 
Traumatic brain injury can reduce striatal dopamine levels. The cause of this is uncertain, but 
is likely to be related to damage to the nigrostriatal system.  We investigated the pattern of 
striatal dopamine abnormalities using 123I-Ioflupane SPECT scans and their relationship to 
nigrostriatal damage and clinical features. We studied 42 moderate-severe traumatic brain 
injury patients with cognitive impairments but no motor parkinsonism signs and 20 healthy 
controls. 123I-Ioflupane scanning was used to assess dopamine transporter levels. Clinical 
scan reports were compared to quantitative dopamine transporter results. Advanced MRI 
methods were used to assess the nigrostriatal system, including the area through which the 
nigrostriatal projections pass as defined from high-resolution Human Connectome Data. 
Detailed clinical and neuropsychological assessments were performed. Around 20% of our 
moderate-severe patients had clear evidence of reduced specific binding ratios for the 
dopamine transporter in the striatum measured using 123I-Ioflupane SPECT. The caudate was 
affected more consistently than other striatal regions. Dopamine transporter abnormalities 
were associated with reduced substantia nigra volume. In addition, diffusion MRI provided 
evidence of damage to the regions through which the nigrostriatal tract passes, particularly 
the area traversed by dopaminergic projections to the caudate. Only a small percentage of 
patients had evidence of macroscopic lesions in the striatum and there was no relationship 
between presence of lesions and dopamine transporter specific binding ratio abnormalities. 
There was also no relationship between reduced volume in the striatal sub-regions and 
reduced dopamine transporter specific binding ratios. Patients with low caudate dopamine 
transporter specific binding ratios show impaired processing speed and executive dysfunction 
compared to patients with normal levels. Taken together, our results suggest that the 
dopaminergic system is affected by a moderate-severe traumatic brain injury in a significant 
proportion of patients, even in the absence of clinical motor parkinsonism. Reduced 
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dopamine transporter levels are most commonly seen in the caudate and this is likely to 
reflect the pattern of nigrostriatal tract damage produced by axonal injury and associated 
midbrain damage. 
 
  
 4 
Introduction 
Traumatic brain injury (TBI) can damage the dopaminergic system. Animal models of TBI 
show both dopaminergic cell loss (van Bregt et al., 2012) and biochemical disturbance of the 
dopaminergic system. Biochemically, a brief transitory rise in dopamine levels throughout 
the brain (Huger and Patrick, 1979; McIntosh et al., 1994; Massucci et al., 2004; Kobori et 
al., 2006) is followed by a functional hypodopaminergic state (Wagner et al., 2005b). Human 
neuropathology studies also show head injuries cause gross and microscopic changes to the 
substantia nigra (Smith et al., 2013).  
The dopaminergic cell bodies reside in two main nuclei in the midbrain, the substantia nigra 
and the ventral tegmental area (Bjorklund and Dunnett, 2007). These nuclei are therefore 
susceptible to midbrain and brainstem injuries that are common after TBI, particularly in 
those patients with poor outcome (Adams et al., 1989). The ascending dopaminergic neurons 
project to subcortical and cortical areas, with striatal projections travelling through the 
nigrostriatal tract. These ascending fibres are likely to be susceptible to damage from 
shearing forces generated by trauma, but this has not previously been investigated. 
Computational models show high strain across the midbrain when subjected to external 
forces as the brain pivots in this region, thereby providing a biomechanical explanation for 
susceptibility to injury in this area (Zhang et al., 2001).  
Striatal dopamine abnormalities can be assessed in vivo using single-photon emission 
computed tomography (SPECT) imaging to measure dopamine transporter (DaT) expression 
(Yan et al., 2002; Wagner et al., 2005a; Wilson et al., 2005; Wagner et al., 2009). This 
imaging technique is widely used in the diagnosis of Parkinson's disease (Marek et al., 1996; 
Wenning et al., 1998; Benamer et al., 2003). DaT is located on presynaptic dopaminergic 
neurons (see Fig. 1.A.) with extracellular dopamine levels and neural activity regulating its 
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expression (Gulley and Zahniser, 2003). DaT levels are reduced secondary to dopaminergic 
cell loss or to a compensatory down-regulation because of reduced dopamine levels. In 
humans, two small imaging studies have shown reduced overall striatal DaT binding using 
SPECT and PET after TBI (Donnemiller et al., 2000; Wagner et al., 2014).  
The striatum is sub-divided into the caudate, putamen and nucleus accumbens, which have 
distinct functions. In Parkinson’s disease, motor abnormalities are associated with early DaT 
reductions in the posterior putamen (Guttman et al., 1997; Ma et al., 2002). As abnormalities 
progress anteriorly to involve the caudate, patients show more cognitive impairment (Ekman 
et al., 2012). Following a single TBI patients rarely show motor parkinsonism features 
(Krauss and Jankovic, 2002), but commonly show cognitive impairments that overlap with 
those seen in Parkinson’s disease (Kehagia et al., 2010). This could be explained by a non-
uniform pattern of DaT abnormalities within the striatum.  
Here we extend this previous work in a large study using a multi-modal imaging approach to 
explore the location of dopaminergic abnormalities within the striatum and its relation to 
structural damage within the nigrostriatal system. 123I-Ioflupane SPECT was used to calculate 
DaT specific binding ratios (SBRs) within the striatum. Advanced diffusion and volumetric 
MRI methods were used to investigate post-traumatic damage to the substantia nigra and 
ascending nigrostriatal fibres defined using high-resolution Human Connectome Project 
(HCP) data (Van Essen et al., 2013). The following hypotheses were tested: (1) DaT levels 
are reduced following moderate-to-severe TBI; (2) DaT levels in areas of the striatum related 
to cognitive functioning (caudate) are affected more than areas associated with motor 
functioning (putamen); (3) evidence of structural damage to the substantia nigra and/or the 
areas through which the ascending nigrostriatal fibres pass relate to reduced striatal DaT 
levels; (4) alterations in striatal DaT levels relate to cognitive impairments; in particular, 
processing speed, attention and executive functions.  
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Materials and methods  
The study was approved by the West London and GTAC NRES Committee (14/LO/0067). 
All participants provided informed consent.  
 
Eligibility, Groups and Screening 
Patients were recruited from specialist TBI clinics in London, UK. Inclusion criteria were: (1) 
aged 20-65; (2) history of single moderate-severe TBI (Mayo classification (Malec et al., 
2007)) at least 3 months prior; (3) subjective complaint of cognitive difficulties by 
participant, treating clinician, or caregiver. Exclusion criteria included: (1) neurological or 
psychiatric illness diagnosed prior to TBI; (2) drug or alcohol addiction; (3) positive urine 
drug screen (4) contraindication to MRI or SPECT; (5) contraindication to methylphenidate 
use (as this study formed part of a clinical trial, which will be reported separately); (6) 
clinical evidence of motor signs of parkinsonism as assessed by a Neurologist. Following 
baseline neuropsychological assessment, SPECT and MRI scans; the TBI patients were 
randomized into a double-blind placebo-controlled cross-over study of methylphenidate, 
which is the subject of a separate publication (in preparation).  
A group of 20 age-matched, healthy control participants were used for the SPECT and MRI 
analyses. They were in good general health with no history of significant illness, and 
ineligible if they met any exclusion criteria above. 
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A screening visit involved medical history and physical examination including the Unified 
Parkinson’s disease rating scale (UPDRS) motor subscale (Goetz et al., 2007). None of the 
patients screened had evidence of motor parkinsonism.  
 
Study Design  
A cross-sectional study of 42 TBI patients compared to 20 controls was performed. All 
participants had 123I-Ioflupane SPECT, MRI including volumetric T1 and diffusion MRI, and 
detailed neuropsychological testing.  
 
Study Procedures 
Study procedures were carried out at the Hammersmith Hospital, Imperial College London 
(London, UK) and Charing Cross Hospital (London, UK). 
123I-Ioflupane Single Photon Emission Computed Tomography  
Before administration of 123I-Ioflupane, patients received potassium iodide tablets (2x60mg) 
to minimize radiation exposure to the thyroid gland. One hour later, a bolus intravenous 
injection of 123I-Ioflupane (GE Healthcare Ltd) was administered to each individual (mean 
activity 185MBq). SPECT images for all subjects were acquired using the same dual-headed 
gamma camera (Symbia T16, Siemens Healthcare) at 180 minutes post-injection with LEHR 
collimators, 128x128 matrix, 1.45 zoom, 128 projections, and 30 seconds per projection. 
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Magnetic resonance imaging 
All participants had a T1-weighted high-resolution MPRAGE scan (160 1-mm-thick 
transverse slices, TR = 2300 ms, TE = 2.98 ms, FA = 9°, in-plane resolution = 1 x 1mm, 
matrix size = 256 x 256, field of view = 25.6 x 25.6 cm). Diffusion-weighted images were 
acquired along 64 non-colinear directions with b=1000s/mm2 and four averages with 
b=0s/mm2, with TE/TR 103/9,500ms, 64 contiguous slices, FoV 256 mm, and voxel size 
2mm3. 
Neuropsychological assessment 
A previously described neuropsychological battery assessed cognitive domains often 
observed to be impaired after TBI (Kinnunen et al., 2011) (Table 1). In addition, 
questionnaires were used to assess apathy (the Lille Apathy Rating Scale (Sockeel et al., 
2006)), fatigue (the Visual Analogue Scale of Fatigue (Lee et al., 1991)), and changes in 
behaviour post-injury (both the ‘self’ and ‘family’ versions of the Frontal Systems Behaviour 
Scale (Grace and Malloy, 2001)). Functional outcome was assessed in patients using the 
Glasgow Outcome Scale-Extended (GOS-E) (Wilson et al., 1998) (Supplementary Table 2). 
 
Image Analysis (Fig. 1) 
123I-Ioflupane Single Photon Emission Computed Tomography  
 Acquired data were reconstructed with an OSEM based iterative algorithm (HybridRecon, 
HERMES Medical Solutions; Stockholm, Sweden) including corrections for attenuation, 
scatter, and resolution (Fig. 1.A.i.).  The reconstructed SPECT images were co-registered 
with their corresponding native T1 MRI image. T1 images were segmented into grey and 
white matter using SPM12, and warped to an average group template using a diffeomorphic 
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nonlinear registration (DARTEL) (Ashburner, 2007). Templates were registered to Montreal 
Neurological Institute 152 (MNI) space. Then the individual flow-fields and template 
transformation from DARTEL were applied to the SPECT images to produce MNI space 
images, without modulation.  
The specific binding ratio (SBR) was calculated for the whole striatum and the caudate, 
putamen and nucleus accumbens separately. The SBR was calculated using the formula 
([region of interest counts − background counts]/background counts) where the background 
counts were calculated from the occipital cortex, an area of low DaT expression. The SBR is 
a semi-quantitative technique that takes into account variations in non-specific uptake of 123I-
Ioflupane between individuals. It makes the assumption that the non-specific uptake is 
equivalent throughout the brain. 
All SPECT images were also independently reported by two nuclear medicine Consultants 
following a predefined ranking scale of normal, abnormal or indeterminate. Any 
discrepancies between reports were resolved by consensus opinion to give a single result per 
scan.  
Lesion Segmentation 
In patients, lesions apparent on T1 MRI were manually segmented and excluded from all 
imaging analyses (Fig. 2). In addition, lesion volumes within the striatum and frontal lobe 
were measured to test for a relationship between the presence and size of lesions and striatal 
SBR. 
Voxel-Based Morphometry (VBM) 
For cross-sectional VBM, T1 images were segmented into grey and white matter, and warped 
to MNI space (as above) but including modulation by the Jacobian determinants (JDs) 
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derived from DARTEL (Fig. 1B). The normalized segmentations were then smoothed (4mm 
FWHM) and masked (group mean p>0.2). Total grey and white matter tissue volumes, and 
intracranial volume (ICV), were calculated using SPM12. A mask of the substantia 
nigra(Keuken et al., 2014) and striatum (derived from the Harvard-Oxford probabilistic 
anatomical atlas within FSL) in MNI space were thresholded at >50% probability and used to 
calculate volumes for these structures in each individual by overlaying on the individual 
normalised volumetric images. 
Diffusion Tensor Imaging (DTI) 
Diffusion-weighted images were preprocessed using standard methods (Kinnunen et al., 
2011) and tensor-based registration performed using DTI-TK (Zhang et al., 2007) (Fig. 1C). 
Maps of fractional anisotropy (FA) and mean diffusivity (MD) were generated from MNI 
space tensor images. A map of the area through which the nigrostriatal tract passes, as well as 
nigro-caudate, nigro-putamen and nigro-nucleus accumbens components of this tract, was 
created using 100 subjects from the HCP (Van Essen et al., 2013). Fibre-tracking was 
performed in both directions between the left and right substantia nigra and the corresponding 
nucleus accumbens, putamen and caudate using the MRtrix package (Tournier et al., 2012). 
3000 tracks were performed with maximum angle between successive steps limited to 45 
degrees. A probability mask based on the percentage of tracks passing through each voxel 
was created for each individual and thresholded at 5%. All masks were binarised and masks 
from the two directions of tracking were combined. A group probabilistic mask that was then 
thresholded at 25% to create a group mask.  
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Statistical Analyses 
Group characteristics were compared using independent sample t-tests (for age) and Fisher’s 
exact test (gender). Voxelwise cross-sectional comparison of 123I-Ioflupane SBR was 
performed using nonparametric permutation tests (Nichols and Holmes, 2002) in FSL (5000 
permutations). Age was added as a nuisance covariate. All results were cluster corrected 
using threshold-free cluster enhancement (Smith and Nichols, 2009) with family-wise error 
rate of p<0.05. For the 123I-Ioflupane SBR region of interest (ROI) analysis, a linear mixed-
effects model was used to assess group differences within the sub-divisions of the striatum 
(caudate, putamen and nucleus accumbens). Group and ROI were defined as fixed effects, 
whereas subject was defined as a random effect to model variability in subject intercepts. Age 
was included as a co-variate. Post-hoc unpaired sample t-tests were used to investigate any 
significant main effects or interactions. To remove the variance in SBR that relates to age 
from these post hoc tests, residuals from a linear regression of age on region SBR were used, 
then differences between patients and controls were assessed per region: caudate, putamen 
and nucleus accumbens. A similar linear mixed-effects model was used for analysis of 
diffusion metrics using multiple ROIs (nigro-caudate, nigro-putamen and nigro-nucleus 
accumbens tracts). Age was included as a co-variate. For volumetric analysis, volumes were 
corrected for total intracranial volume to remove differences caused by head size, and age 
was added as a nuisance co-variate. Substantia nigra volumes were compared using an 
unpaired sample t-test. To assess the sub-divisions of the striatum a mixed-effects model was 
used followed by post-hoc unpaired sample t-tests. To explore the relationship between the 
structural measures (substantia nigra volume and tract diffusivity measures) and 123I-
Ioflupane SBR we used linear regression to predict striatal sub-region SBR with the structural 
measure and group (i.e. patient or control) as explanatory variables and age (and intracranial 
volume for volumetric measures) as nuisance variables. 
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Differences in performance on neuropsychological tests and questionnaires for patients and 
controls were investigated with the use of Wilcoxon Rank Sum Tests for independent 
samples and corrected for multiple comparisons using the false discovery rate method. 
Subjects greater than 3 standard deviations from the mean on tests were considered outliers 
and removed from further analysis. This applied to four subjects in the Choice Reaction Task 
(one control removed for prolonged reaction time, two patients for excessive misses and one 
patient for excessive errors), one control in the People’s Test and two patients in the Trail 
Making task. One control and one patient were also removed from the Choice Reaction Task 
analysis due to faulty equipment on the day of testing. 
To explore the relationship between neuropsychological performance and 123I-Ioflupane 
SBR, patients were split based on their clinical 123I-Ioflupane scan report and also based on 
the quantitative analysis using both one standard deviation and two standard deviations below 
the control mean for caudate, putamen, nucleus accumbens and whole striatum. 
Statistical analysis and graph illustration were performed using R version 3.3.2 
(http://www.R-project.org/). 
 
Results 
Baseline characteristics 
Forty-two TBI patients and 20 healthy controls were enrolled. Patients comprised 36 males 
(86%) with mean age 39.8 years (standard deviation 11.7, range 20-65). Median time since 
injury was 34 months (range 6-366 months) (Supplementary Table 1). There was no 
significant age difference with the healthy controls (16 males (80%), mean age±s.d. 
40.2±12.9, range 21-61). Thirty patients had one or more focal lesions (Fig. 2). The majority 
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of lesions appeared in frontal and/or temporal lobes. No patients had focal lesions in the 
substantia nigra. Six patients had lesions involving the striatum. These lesions were all very 
small with the largest lesion load for a single patient comprising just 5% of the total striatal 
volume (range 0.8-5.0%, mean 3.1%). Lesioned areas were masked out of further analyses. 
 
Clinical reports of 123I-Ioflupane scans 
A third of patients (14/42) had abnormal 123I-Ioflupane scans on clinical reporting (Fig. 3 and 
Fig. 4). No controls had scans reported as abnormal on clinical classification. Three controls 
and three patients were clinically classified as indeterminate. The pattern of loss of uptake 
was most often described as patchy. At the individual level, abnormalities were sometimes 
apparent throughout the striatum including the putamen and caudate, although these were 
often inconsistent across individuals. 
 
Patients show reduced 123I-Ioflupane specific binding ratios in the caudate 
Across the whole group, whole-brain voxelwise analysis showed patients had significantly 
lower SBR in the anterior striatum, with significant differences found exclusively in the 
caudate (Fig. 5A and 5B). SBR was not reduced in the putamen across the group. We then 
used a region of interest approach to explore the effect of TBI on striatal sub-regions (Fig. 
5C). A mixed-effects model including the caudate, putamen and nucleus accumbens showed 
a region of interest by group interaction (F(2,120)=3.08, p=0.0495). This was driven by a 
significantly lower SBR in the caudate for patients compared to controls (t(40.5)=-3.48, 
p=0.001), with a difference that approached significance in the putamen (p=0.052) and no 
difference in the nucleus accumbens (p=0.236). The effect size for differences in caudate 
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SBR was large (Cohen’s d=0.92, 95% CI [0.35, 1.49]), but small in the putamen (Cohen’s 
d=0.50, 95% CI [-0.05, 1.05]) and nucleus accumbens (Cohen’s d=0.32, 95% CI [-0.23, 
0.86]). 
 
Classifying individual patients 123I-Ioflupane scans 
Clinical classification was compared with quantitative results (Fig. 4). To allow comparison 
between the two sets of results scans clinically classified as ‘indeterminate’ were grouped 
with ‘normal’ scans. In addition, we categorised patients on quantitative results into normal 
and abnormal using two criteria; (i) greater than 1 standard deviation (s.d.) below the mean 
SBR in the control group; and (ii) greater than 2 s.d. below the mean SBR. The more 
stringent criteria (2 s.d.) gave consistent results to the clinical classification with no false-
positives in the control population. Using this approach, 8 patients were classified as 
abnormal based on striatal SBR and 7 based on caudate or putamen SBR. All these patients 
were also classified as abnormal on clinical assessment. The less stringent criterion (1 s.d.) 
led to three false positives in the controls and as expected more patients classified as 
abnormal (16 in the striatum, 18 in the caudate and 15 in the putamen). Classification based 
on the whole striatum (2 s.d.) showed the greatest concordance with the clinical classification 
(Cohen’s Kappa=0.67). Whole striatum (1 s.d.) also showed reasonable agreement with the 
clinical classification (Cohen’s Kappa=0.55), albeit with more ‘false positives’ classified in 
the quantitative group. 
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Processing speed and functional outcome relate to 123I-Ioflupane scan 
abnormalities 
Over the whole group, TBI patients showed impaired performance in a range of cognitive 
domains, including tests of processing speed, memory and executive function when 
compared with the control group (Table 1). Patients also reported significantly increased 
apathy, fatigue and executive dysfunction compared to controls, a finding that was 
corroborated on caregiver questionnaires (Supplementary Table 2).  
Patients with significantly reduced caudate DaT levels as defined using the 2 s.d. criteria 
showed impairments in measures of processing speed of varying complexity compared to 
patients with normal caudate DaT levels. Specifically, abnormal patients were significantly 
slower on simple measures of processing speed including the Trail Making Test A (W=177, 
p=0.027) and Stroop Colour Naming & Word Reading Composite Score (W=181.5, p=0.045) 
as well as on the more complex Stroop Inhibition-Switching Task (W=189.5, p=0.022) 
(Supplementary Fig. 3). Functional outcomes as defined by the GOS-E were also worse in 
these patients (W=66, p=0.033). There were no differences in neuropsychological measures 
using the less stringent classification criterion (1 s.d.). Patients defined as abnormal on the 
clinical report did not show any difference on cognitive measures but did have worse 
outcome on the GOS-E (W=130, p=0.048). Changes in 123I-Ioflupane SBR in the whole 
striatum and putamen did not relate to cognitive measures. 
 
UPDRS score relates to 123I-Ioflupane scan abnormalities 
None of our patients had evidence of clear motor parkinsonism, which is usually the case 
after single TBI (Krauss and Jankovic, 2002). Despite this, six patients had high UPDRS 
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motor subscale scores (>9) (Racette et al., 2006) (Fig. 6), which was due to pyramidal or 
cerebellar signs on examination. Patients with abnormal 123I-Ioflupane clinical reports had 
significantly higher UPDRS scores than patients with normal reports (W=113, p=0.002). This 
was also true for those patients with abnormal striatal (W=90.5, p=0.037) or abnormal 
caudate SBR using the 2 s.d. criteria (W=51, p=0.002). For the caudate, this relationship was 
also present with the less stringent 1 s.d. criteria (W=151, p=0.027). Putamen SBR did not 
relate to UPDRS score using either classification (both p>0.2). 
 
Patients showed reduced volume of the substantia nigra and all sub-divisions of 
the striatum 
The substantia nigra was significantly smaller in patients compared to controls (t(51.3)=-
3.54, p<0.001) (Fig. 7A). In addition, all three striatal sub-regions were significantly smaller 
in patients compared to controls; caudate (t(37.69)=-3.45, p=0.001), putamen (t(46.0)=-4.26, 
p<0.001) and nucleus accumbens (t(49.5)=-4.17, p<0.001).  
 
Substantia nigra volume is related to 123I-Ioflupane specific binding ratios 
Substantia nigra volume was related to caudate and putamen SBR. Linear regression showed 
substantia nigra volume was related to caudate SBR (b=3.38, SE=1.63, t=2.07, p=0.04), such 
that low volume was associated with low SBR (Fig. 7A). There was no significant interaction 
between group and substantia nigra volume (p=0.76), but the relationship was present when 
examining the patient group alone (b=3.83, SE=1.86, t=2.06, p=0.04). Substantia nigra 
volume was also related to putamen SBR (b=3.28, SE=1.63, t=2.01, p=0.04). Again, there 
was no interaction between group and substantia nigra volume (p=0.77). Substantia nigra 
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volume was not related to nucleus accumbens SBR, although the relationship was close to 
significance (p=0.06). The volumes of the caudate, putamen and nucleus accumbens were not 
related to their respective SBRs (caudate p=0.58, putamen p=0.26, nucleus accumbens 
p=0.21).  
 
Patients show damaged nigrostriatal connections to the caudate 
We next examined nigrostriatal tract structure, defined from analysis of high-resolution HCP 
data. Patients showed significantly higher MD in the white matter area through which the 
nigrostriatal tract passes (t(63.2)=3.39, p=0.001) (Fig. 7B). There was no difference in FA 
between patients and controls (t(41.6)=-0.69, p=0.494). We explored connections to sub-
regions within the striatum. A mixed-effects model showed an interaction between tract and 
group (F(2,120)=8.7, p<0.001), which resulted from a significantly higher MD in the nigro-
caudate tract for patients compared to controls (t(57.9)=3.48, p<0.001) with no difference in 
the nigro-putamen (p=0.3) or nigro-nucleus accumbens tracts (p=0.2). Analyses of FA in 
these tracts did not reveal any differences between the groups (nigro-caudate tract, p=0.4; 
nigro-putamen tract, p=0.08; nigro-nucleus accumbens tract, p=0.3). 
 
Nigrostriatal tract structure is related to substantia nigra volume  
Linear regression showed substantia nigra volume was related to MD in the nigrostriatal tract 
(b=-0.31, SE=0.10, t=-3.11, p=0.003), such that low volume was associated with high MD. In 
contrast, there was no significant relationship between MD in the nigrostriatal tract and 
striatal SBR (p=0.081) or between MD in the nigro-caudate tract and caudate SBR (p=0.078), 
although both these relationships approached significance.  
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The presence of frontal lobe or striatal lesions does not alter striatal SBR 
Twenty-three patients had visible frontal lobe lesions on T1 imaging. These patients did not 
have a significant reduction in SBR in the whole striatum or its sub-regions compared to 
patients with no frontal lobe lesions and controls. In addition, there was no relationship 
between the size of frontal lobe lesions and SBR in the whole striatum or its sub-regions. Six 
patients had visible lesions in their caudate, three in the putamen and two in the nucleus 
accumbens. Patients with lesions in these structures did not have different SBRs compared to 
patients without lesions (caudate p=0.46, putamen p=0.97, nucleus accumbens p=0.38).  
 
Discussion 
One third of our moderate-severe TBI patients had abnormal striatal DaT on clinical 
reporting of 123I-Ioflupane SPECT scans. The caudate was affected to a greater extent than 
other striatal regions. However, at the individual level there was a large degree of variability, 
with some patients showing clear abnormalities in the other regions of the striatum. DaT 
abnormalities in the caudate were associated with reduced substantia nigra volume, and there 
was evidence of nigrostriatal tract damage particularly affecting projections to the caudate. 
Taken together our results suggest that the dopaminergic system is commonly affected by 
TBI. The caudate is most commonly affected although all areas of the striatum can be 
disrupted. Within individuals, the pattern of striatal abnormality is likely to reflect the 
location of nigrostriatal tract damage produced by axonal and midbrain damage. 
Our findings extend the two previous imaging studies in humans demonstrating altered DaT 
levels in the striatum after TBI (Donnemiller et al., 2000; Wagner et al., 2014).  Donnemiller 
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and colleagues found more than 50% reduction in striatal DaT binding using the SPECT 
tracer [123I]β-CIT in a group of ten patients who were in a vegetative state or had persisting 
akinetic-rigid features. Wagner and colleagues studied a less severe group of 12 
moderate/severe TBI patients and found a 15% striatal reduction using the PET ligand [11C]β-
CFT. Our patients were of similar severity to Wagner’s study and we showed a similar 
magnitude of reduction in DaT (11% for whole striatum). Therefore, the three studies 
together suggest that reductions in striatal DaT are dependent on injury severity.  
Our results are also in line with animal models of TBI, which show reduced DaT expression 
in the striatum (Yan et al., 2002; Wagner et al., 2005b; Shimada et al., 2014). The DaT 
resides on presynaptic dopaminergic neurons, therefore loss of dopaminergic fibres results in 
reduced DaT levels. In addition, synaptic dopamine levels rapidly affect DaT expression 
(Gulley and Zahniser, 2003). Therefore, the hypodopaminergic state seen post-traumatically 
will lead to a compensatory down-regulation in DaT expression (Bales et al., 2009). Animal 
work suggests that functional down-regulation is the main driver of reduced DaT levels post-
traumatically as other markers of dopaminergic cell density were unaffected (Wagner et al., 
2005b).  
Our SPECT results are compatible with functional down-regulation of DaT, but the MRI 
assessment suggests that dopaminergic cell loss may also be a factor. Reduced substantia 
nigra volume indicates cell loss in this region, which correlates with striatal DaT binding. 
This is likely to be at least partly due to direct damage to the cell bodies in the nuclei 
themselves. Brainstem nuclei are susceptible to the effects of trauma (Adams et al., 1989). 
Focal injury is often seen in the midbrain and computational models of TBI demonstrate high 
strain in the midbrain as the brain pivots in this region (Zhang et al., 2001). In addition, 
neuropathological studies in humans who have suffered repetitive head injuries show gross 
and microscopic changes to the substantia nigra (Smith et al., 2013).   
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In addition to direct damage to the midbrain nuclei, dopaminergic neurons may suffer axonal 
injury to their projecting fibres leading to Wallerian degeneration and subsequent cell death 
of substantia nigra neurons. Animal models show that substantia nigra damage can be 
produced as a remote effect of cortical injury (van Bregt et al., 2012). This can result from 
damage to long-distance axonal projections that are vulnerable to the deforming forces 
generated by the acceleration and deceleration of the brain during trauma (Gennarelli et al., 
1982). The ascending nigrostriatal dopaminergic axons may be particularly vulnerable as 
they are poorly or unmyelinated (Reeves et al., 2005; Staal and Vickers, 2011). We used 
high-resolution diffusion MRI data from the HCP to define the locations of the nigrostriatal 
projections and applied the results to assess nigrostriatal tract damage. A limitation of the 
diffusion results is that the nigrostriatal tracts cannot be specifically resolved and only make 
up a small percentage of the fibres in the white matter area studied. However, diffusion 
abnormalities were seen in the white matter through which the nigrostriatal tract passes. This 
reduction correlated with substantia nigra volume, suggesting that cell death in this region 
was linked to axonal injury within the nigrostriatal tract.  
A striking feature of our results is that post-traumatic changes in DaT levels were 
predominantly seen in the caudate. This was not due to focal injury within the caudate, as few 
patients had visible lesions in their striatum and there was no relationship between lesion 
presence and DaT SBRs. In addition, we didn’t observe a more subtle relationship between 
the volume of striatal sub-regions and DaT SBRs that would indicate a non-specific effect of 
atrophy. In contrast, our results provided evidence that caudate DaT might be particularly 
disrupted because of the high levels of damage within nigrostriatal fibres projecting to the 
caudate. Taken together the pattern of nigrostriatal tract damage and the relationship between 
tract damage, substantia nigra volumes and DaT binding suggests that nigrostriatal 
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projections to the caudate might be particularly vulnerable following TBI and that damage to 
these projections preferentially reduces caudate dopamine after TBI.  
TBI patients with very low levels of caudate DaT showed evidence of processing speed and 
executive function abnormalities. Similar relationships between dopaminergic function and 
cognition have been shown in healthy individuals (Mozley et al., 2001), patients with 
Parkinson’s disease (Marie et al., 1999; Muller et al., 2000) and patients with Huntington’s 
disease (Backman et al., 1997). Executive functions and processing speed are thought to rely 
on intact functioning of cortico-striatal circuitry, which links the frontal cortex and caudate 
and is mediated by dopaminergic neurotransmission (Divac et al., 1967; Backman et al., 
1997). Dopaminergic therapies in Parkinson’s disease ameliorate at least some of the 
associated cognitive impairments (Cools et al., 2002; Mattay et al., 2002). Therefore, TBI 
patients with evidence of dopaminergic dysfunction may benefit from dopaminergic 
medications for cognitive impairments and DaT neuroimaging might be a useful way to 
predict treatment response or stratify treatment selection.   
Previous work has shown TBI patients with obvious parkinsonism display striatal DaT 
abnormalities (Donnemiller et al., 2000). Here none of our patients were parkinsonian, which 
is the case for the vast majority of TBI patients (Krauss and Jankovic, 2002). Despite the 
absence of parkinsonism, our patients showed frequent evidence of striatal dopamine 
abnormalities. The lack of parkinsonism might reflect the location of striatal dopaminergic 
abnormalities, which were more pronounced in the caudate. Dopaminergic depletion in 
Parkinson’s disease initially occurs in the posterior putamen and reduced DaT levels in this 
region relate to motor signs (Guttman et al., 1997; Ma et al., 2002). At the group level, our 
patients did not have a significant reduction of DaT in the putamen. However, some 
individuals had clear reductions in putaminal DaT levels. This might be due to the severity of 
dopaminergic changes.  At the time of symptom onset in Parkinson’s disease there is usually 
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over 50% reduction in DaT levels (Cheng et al., 2010). None of our patients had reductions 
in DaT to this degree, therefore the impact of TBI on the dopaminergic system maybe below 
the threshold required to display overt signs of parkinsonism. However, TBI patients with 
evidence of reductions in DaT levels might be predisposed to the future development of 
parkinsonism. Our work does not provide information about the long-term significance of 
reduced DaT, which is a limitation of the cross-sectional study design. Further longitudinal 
studies will be needed to inform how these abnormalities evolve and to what extent DaT 
abnormalities are a risk factor for late deterioration.  
Our in vivo imaging assessment uses a semi-quantitative technique, which assumes that non-
specific uptake of 123I-Ioflupane is equivalent throughout the brain. Therefore, if TBI caused 
variable changes to this non-specific uptake in different brain regions (e.g. through changes 
to striatal absorption of 123I-Ioflupane) this could bias the results. We have no reason to 
suspect distinct non-specific uptake across the striatum to explain the pattern of abnormalities 
we observed and our results are also in line with animal models of TBI using different 
techniques, which also show reduced DaT expression in the striatum (Yan et al., 2002; 
Wagner et al., 2005b; Shimada et al., 2014). 
In conclusion, striatal DaT abnormalities measured using 123I-ioflupane SPECT were 
commonly seen following moderate/severe TBI. One third of the SPECT scans were 
clinically reported as abnormal. These changes are a marker of reduced striatal dopamine. 
Our results suggest this is due to the pattern of nigrostriatal tract damage produced by axonal 
injury. Cognitive impairment was greater in patients with marked reductions in caudate DaT 
and similar cognitive impairments respond to dopaminergic treatments in other contexts. 
Therefore, DaT abnormalities following TBI may assist treatment selection after TBI. 
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Figure Legends: 
Figure 1. Methods: A. (i) 123I-Ioflupane SPECT scan analysis: Individual reconstructed 
123I-Ioflupane SPECT scans were co-registered with their native T1 MRI using rigid 
transformation. T1 images were warped to an average group template using a diffeomorphic 
nonlinear registration (DARTEL). Templates were registered to Montreal Neurological 
Institute 152 (MNI) space. Then the individual flow-fields and template transformation from 
DARTEL were applied to the SPECT images to produce MNI space images, without 
modulation. (ii) Schematic of a dopaminergic synapse illustrating the role of the pre-synaptic 
DaT in re-uptaking synaptic dopamine: DOPA=L-3,4-dihydroxyphenylalanine, 
DA=Dopamine, nvDA=Non vesicular dopamine, VMAT2=Vesicular monoamine transporter 
2, DAT=Dopamine transporter, TH=Tyrosine hydroxylase, L-AAD=L-amino acid 
decarboxylase,B. Volumetric MRI analysis: T1 images were warped to MNI space (as above) 
but including modulation by the Jacobian determinants derived from DARTEL. A mask of 
the substantia nigra and striatum in standard space were used to calculate volumes for these 
structures in each individual. C. Diffusion MRI analysis: (i) Making the nigrostriatal mask: 
Fibre-tracking using the MRtrix package was performed on 100 subjects from the Human 
Connectome Project (HCP) to create binarised masks for the nigro-striatal tract as a whole, as 
well as the sub-regions; nigro-caudate, nigro-putamen and nigro-nucleus accumbens tracts; 
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(ii) Processing diffusion data: Diffusion-weighted images were preprocessed using standard 
methods and tensor-based registration performed using DTI-TK. 
Figure 2. Lesion map: Thirty patients had focal lesions visible on T1 MRI. These were 
overlaid to produce a lesion map. Maximal areas of overlap of lesions were seen in the 
anterior frontal and temporal lobes. There were no lesions in the substantia nigra (light blue) 
and minimal lesion load in the striatum (green) and in the area through which the nigrostriatal 
tract passes (dark blue).  
Figure 3. 123I-ioflupane SPECT scan examples: A selection of 16 TBI patients and 3 
controls. Subject’s age, gender (M/F) and the time since injury in months is shown. The 
colour scale shows the 123I-Ioflupane SBR. 
Figure 4. Clinical 123I-ioflupane SPECT scan reports and quantitative comparison: 
Comparison between individual clinical reporting and quantitative assessment of 123I-
ioflupane SPECT scans: Each line represents a single subject. Red signifies ‘abnormal’ and 
blue ‘normal’. For the quantitative assessment in the whole striatum, caudate and putamen 
two criteria were used; greater than 1 and greater than 2 standard deviations standard 
deviation (SD) below the mean SBR in the control group. 
Figure 5. 123I-ioflupane SPECT scan results: A. Results of the voxelwise analysis: areas 
of significant reduction of 123I-Ioflupane SBR are shown in red/yellow. The striatal mask is 
shown for comparison in blue. The colour bar shows the corrected p-values. B. Anatomical 
location of the caudate, putamen and nucleus accumbens for reference. C. Region of interest 
analyses: Plots show 123I-Ioflupane SBR corrected for age for patients and controls in the 
caudate, putamen and nucleus accumbens. The SBR corrected for age are the residuals from 
the linear regression of age on SBR. ** Signifies p=0.001. 
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Figure 6. Characteristics of patients with UPDRS motor sub-score greater than nine: 
Clinical details of the six patients with UPDRS scores higher than nine. Examination findings 
are included along with a functional outcome measure (GOS-E), UPDRS score and an axial 
slice of their 123I-Ioflupane scan. 
Figure 7. Volumetric and diffusion tensor MRI results: A. Volumetric assessment: Top 
line of plots shows volume corrected for intracranial volume for patients and controls in the 
substantia nigra, caudate, putamen and nucleus accumbens. Bottom two plots show 123I-
Ioflupane SBR of the caudate and putamen (corrected for age) correlate positively with 
substantia nigra volume (corrected for age and intracranial volume). Patients are in red and 
controls in blue. The SBR and volumes corrected for age are the residuals from the linear 
regression of age on SBR and volume. Key at the bottom shows masks used for volumetric 
analysis of the different regions. B. Diffusivity assessment: Top line of plots shows mean 
diffusivity corrected for age for patients and controls in the nigro-striatal, nigro-caudate, 
nigro-putamen and nigro-nucleus accumbens tracts. Bottom two plots show 123I-Ioflupane 
SBR of the whole striatum and caudate (corrected for age) correlate negatively with the mean 
diffusivity of the nigro-striatal and nigro-caudate tracts (corrected for age) respectively. 
Patients are in red and controls in blue. ** Signifies p<0.01, SBR=specific binding ratio, 
rs=Spearman’s rho, MD=Mean diffusivity. The SBR and mean diffusivities corrected for age 
are the residuals from the linear regression of age on SBR and mean diffusivity. Key at the 
bottom shows the masks used for the nigro-putamen, nigro-caudate and nigro-nucleus 
accumbens tracts (the nigro-striatal tract was all three combined). 
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